Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
Olivier ColombanAndrew ClampAdrian CookIain A McNeishBenoit YouPublished in: JCO clinical cancer informatics (2023)
Fractionated dose-dense chemotherapy might be beneficial for patients belonging to the poor prognostic group characterized by lower tumor chemosensitivity assessed with the online calculator CA-125-Biomarker Kinetics and incomplete debulking surgery. Further investigation in the future SALVOVAR trial is warranted.
Keyphrases
- end stage renal disease
- study protocol
- phase iii
- clinical trial
- ejection fraction
- newly diagnosed
- locally advanced
- chronic kidney disease
- minimally invasive
- phase ii
- prognostic factors
- neoadjuvant chemotherapy
- social media
- patient reported outcomes
- squamous cell carcinoma
- small cell lung cancer
- coronary artery bypass
- healthcare
- radiation therapy
- surgical site infection
- rectal cancer